References
- Axelrod J. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacological Reviews 1966; 18: 95–113
- Baillie T. A., Neill E., Hughes H., David D. L., Davies D. S. Application of stable isotope labeling in studies of the metabolism of clonidine in rat liver. Stable Isotopes; Proceedings of the Third International Conference. Academic Press, London 1979; 415–425
- Billets S., Lietman P. S., Fenselau C. Mass spectral analysis of glucuronides. Journal of Medicinal Chemistry 1973; 16: 30–33
- von Darda S., Forster H. ‐J., Stahle H. Metabolischer Abbau von clonidine. Arzneimittel‐Forschung/Drug Research 1978; 28(II)255–259
- Fenselau C., Johnson L. P. Analysis of intact glucuronides by mass spectrometry and gas chromatography‐mass spectrometry. A review. Drug Metabolism and Disposition 1980; 8: 274–283
- Guldberg H. C., Marsden C. A. Catechol‐O‐methyl transferase: pharmacological aspects and physiological role. Pharmacological Reviews 1975; 27: 135–206
- Ishii J., Itabashi A., Katayama S., Inaba M., Negishi K., Suzuki M., Kawazu S. Effect of midaglizole (DG‐5128), a new type of oral hypoglycemic agent, on aggregation of platelets from human diabetics. Acta Pharmacologica et Toxicologica, Supplement V 1986; 52
- Ishikawa F. Cyclic guanidines. X. Synthesis of 2‐(2,2‐disubstituted ethenyl‐ and ethyl)‐2‐imidazolines as potent hypoglycemics. Chemical and Pharmaceutical Bulletin, (Tokyo) 1980; 28(5)1394–1402
- Kameda K., Koyama I., Abiko Y. Comparative study on the effects of a hypoglycemic 2‐substituted‐2‐imidazoline derivative (DG‐5128) and tolbutamide on insulin secretion from insulin synthesis in the isolated rat pancreatic islets. Biochemica et Biophysica Acta 1981; 677: 263–268
- Kameda K., Ono S., Abiko Y. Hypoglycemic action of 2‐‘2‐(4,5‐dihydro‐1H‐imidazol‐2‐yl)‐1‐phenylethyl’pyridine dihydrochloride sesquihydrate (DG‐5128), a new hypoglycaemic agent. Arzneimittel‐Forschung/Drug Research 1982a; 32(1)39–44
- Kameda K., Ono S., Koyama I., Abiko Y. Insulin releasing action of 2‐‘2‐(4,5‐dihydro‐1H‐imidazol‐2‐yl)‐1‐phenylethyl’pyridine dihydrochloride sesquihydrate (DG‐5128) a new orally effective hypoglycaemic agent. Acta Endocrinologica 1982b; 99: 410–415
- Kashiwagi A., Harano Y., Suzuki M., Kojima H., Harada M., Nishino Y., Shigeta Y. New α2‐adrenergic blocker (DG‐5128) improves insulin secretion and in vivo glucose disposal in NIDDM patients. Diabetes 1986; 35: 1085–1089
- Kawazu S., Suzuki M., Watanabe T., Ishii J., Nomura H., Hakusui H. Studies of DG‐5128, a new type of oral hypoglycemic drug, in healthy subjects. Diabetes 1984; 33: 87A, (Suppl.)
- Loh A. C., Williams T. H., Tilley J. W., Sasso G. J., Carbone J. J., Toome V., Leinweber F. ‐J. The metabolism of 14C‐cibenzoline in dogs and rats. Drug Metabolism and Disposition 1986; 14: 325–330
- Muramatsu I., Chshita M., Yamanaka K. Selective alpha‐2 blocking action of DG‐5128 in the dog mesenteric artery and rat vas deferens. Journal of Pharmacology and Experimental Therapeutics 1983; 227: 194–198
- Nakaoka M., Hakusui H. Identification of the metabolites of a new hypoglycaemic agent, midaglizole in dogs. Xenobiotica 1987; 17(11)1329–1339
- Nomura H., Hakusui H., Kawazu T., Ishii A. Pharmacokinetics of a new hypoglycemic agent, DG‐5128, in man. Japanese Journal of Clinical Pharmacology and Therapeutics 1984; 15: 43–44
- Yamanaka K., Kigoshi S., Muramatsu I. The selectivity of DG‐5128 as an α2‐adrenoceptor antagonist. European Journal of Pharmacology 1984; 106: 625–628
- Yamanaka K., Kigoshi S., Muramatsu I. Selective interaction of DG‐5128 with a low agonist affinity state of alpha‐2‐adrenoceptor. Japanese Journal of Pharmacology 1985; 37: 293–295